GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prenetics Global Ltd (NAS:PRE) » Definitions » EPS without NRI
中文

Prenetics Global (Prenetics Global) EPS without NRI : $9.93 (TTM As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Prenetics Global EPS without NRI?

Prenetics Global's earnings per share without non-recurring items for the three months ended in Sep. 2023 was $-1.13. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2023 was $9.93.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -82.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Prenetics Global's EPS without NRI or its related term are showing as below:

PRE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -82.9   Med: -82.9   Max: -82.9
Current: -82.9

During the past 4 years, Prenetics Global's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -82.90% per year. The lowest was -82.90% per year. And the median was -82.90% per year.

PRE's 3-Year EPS without NRI Growth Rate is ranked worse than
98.28% of 174 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.25 vs PRE: -82.90

Prenetics Global's EPS (Diluted) for the three months ended in Sep. 2023 was $-1.20. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-4.20.

Prenetics Global's EPS (Basic) for the three months ended in Sep. 2023 was $-1.20. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-4.20.


Prenetics Global EPS without NRI Historical Data

The historical data trend for Prenetics Global's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prenetics Global EPS without NRI Chart

Prenetics Global Annual Data
Trend Dec19 Dec20 Dec21 Dec22
EPS without NRI
-2.72 0.16 -20.21 -16.62

Prenetics Global Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.12 13.41 -1.17 -1.18 -1.13

Competitive Comparison of Prenetics Global's EPS without NRI

For the Diagnostics & Research subindustry, Prenetics Global's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prenetics Global's PE Ratio without NRI Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prenetics Global's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Prenetics Global's PE Ratio without NRI falls into.



Prenetics Global EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prenetics Global  (NAS:PRE) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Prenetics Global EPS without NRI Related Terms

Thank you for viewing the detailed overview of Prenetics Global's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Prenetics Global (Prenetics Global) Business Description

Traded in Other Exchanges
N/A
Address
Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong, HKG
Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong.